- Molecular NameVardenafil
- SynonymVDN
- Weight488.613
- Drugbank_IDDB00862
- ACS_NO224785-90-4
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)0.88
- pkaN/A
- LogD (pH=7, predicted)-0.4
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.56
- LogSw (predicted, AB/LogsW2.0)0.1
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors1
- No.of HBond Acceptors10
- No.of Rotatable Bonds8
- TPSA117.51
- StatusFDA approved
- AdministrationN/A
- PharmacologyA PDE5 inhibitor used for treating impotence (erectile dysfunction)
- Absorption_valueN/A
- Absorption (description)Vardenafil is rapidly absorbed with absolute bioavailability of approximately 15%.
- Caco_2N/A
- Bioavailability15.0
- Protein binding95.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmVardenafil is metabolized predominantly by the hepatic enzyme CYP3A4, with contribution from the CYP3A5 and CYP2C isoforms. The major circulating metabolite, M1, results from desethylation at the piperazine moiety of vardenafil. M1 shows a phosphodiesterase selectivity profile similar to that of vardenafil and an in vitro inhibitory potency for PDE5 28% of that of vardenafil.
- Half life4~5 h
- ExcretionBiliary
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include vision changes and back and muscle pain.
- LD50 (rat)N/A
- LD50 (mouse)N/A